CAR-T 치료제 개발 전문기업 큐로셀은 440억원 규모의 ‘시리즈C’ 투자 유치에 성공했다고 10일 밝혔다. 2017년 창업 이후 큐로셀의 누적 투자유치금은 615억원에 달한다.
큐로셀은 이번 투자유치를 기반으로 CAR-T 치료제 후보 물질인 ‘CRC01’의 연내 임상 개시와 후속 물질 개발을 가속화한다는 방침이다.
[김예나 기자 yena@hankyung.com]
Jong Ran Kim
Head of Clinical Development Center
Executive Vice President
Hyeun Jin Seo
Director
Regulatory Affairs
Mi Kyung Kim, Ph.D.
Director
External R&D
Hyerim Kang
Director
Managing Director of Clinical Project Management
Changwan Hong, Ph.D.
Associate professor, Department of Anatomy, PNU School of Medicine
Outside director
Suhee Cho
Director
Clinical development Advisor
Daniel Ryu
Law office Cheongdang Partner Attorney
Auditor
Jin Kyong Park
Chief Financial Officer
CFO / Director
Hyun-Bo Sim, Ph.D.
Ewha Womans University Associate Professor of department of Bioinspired Science
Gunsoo Kim
CEO
Hyeong Cheol Kim, Ph.D
Executive Director
Head of R&D Center
Chanhyuk Kim, Ph.D.
KAIST Assistant Professor of Department of Life Sciences
Jung Hee Lim
Intervest Executive Director
Director
Head of production Engneering Center
Director
